Is Scholar Rock Holding (SRRK) Undervalued After Its 9.8% Jump?

Scholar Rock Holding (SRRK) has drawn fresh attention after a sharp single day move of 9.8%, putting recent performance and expectations for this rare disease focused biotech back under the microscope for investors.

At a share price of $51.55, Scholar Rock Holding has seen short term momentum pick up, with a 7 day share price return of 20.14% and a 30 day gain of 22.19%. The 1 year total shareholder return of 75.52% and very large 3 year total shareholder return of more than 4x suggest that recent moves are building on an already strong longer term rerating rather than a standalone spike in sentiment.

Scan how Scholar Rock Holding compares with other rare disease and biotech movers by reviewing the hand picked 36 healthcare AI stocks shaping sentiment right now.

Bulls see Scholar Rock Holding as a rare disease leader gaining traction, while bears point to ongoing losses and clinical risk. The next step is to test which story current pricing actually reflects.

Most Popular Narrative: 27% Undervalued

On the analyst consensus Narrative on Simply Wall St, Scholar Rock Holding screens as undervalued, with a fair value of $70.44 against the latest close at $51.55, framing the current share price as a discount to modeled future cash generation.

Scholar Rock Holding currently has no revenue. Analysts are forecasting revenue to reach $538.3 million by September 2029.

If Scholar Rock Holding's profit margin were to converge on the industry average, you could expect earnings to reach $92.4 million (and earnings per share of $0.62) by about September 2029, up from -$408.6 million today.

See why 2 investors see Scholar Rock Holding as 27% undervalued.

That Narrative leans on a discount rate of 7.53%, rapid forecast revenue expansion from a current base of effectively zero, and a future profit margin in line with the wider US biotech sector. It also implies a high future P/E multiple of about 141x on those 2029 earnings, which is well above the 17.1x level cited for the industry in the Narrative. Readers may want to judge for themselves whether that premium is reasonable for Scholar Rock Holding’s pipeline, approval milestones and commercial rollout risk.

Result: Fair Value of $70.44 (UNDERVALUED)

Still, the Scholar Rock Holding story leans heavily on smooth ISEMBYLD launch execution and timely FDA reinspection outcomes, both of which could either upset or validate today’s valuation narrative.

Find out about the key risks to this Scholar Rock Holding narrative.

Next Steps

Mixed on Scholar Rock Holding after reading this far. Move quickly from headline moves to hard numbers by weighing up the 3 key rewards and 3 important warning signs.

Looking for more Scholar Rock Holding sized ideas?

If you stop with Scholar Rock Holding, you risk missing other opportunities. Put a little time into fresh ideas now so your future self has options.

• Target potential bargains early by scanning the 33 high quality undervalued stocks that combine solid fundamentals with prices the market has not fully rewarded yet.
• Prioritise resilience by reviewing a list of solid balance sheet and fundamentals (25 results) that can better handle shocks and still keep funding growth plans.
• Hunt for overlooked potential by checking the 19 high quality undiscovered gems that have quality metrics but limited attention from the crowd so far.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com